drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01381 | DB09122 | 958 | 1,613 | [
"DDInter819",
"DDInter1409"
] | Ginkgo biloba | Peginterferon beta-1a | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
958,
24,
1613
]
],
[
[
958,
63,
1503
],
[
1503,
24,
1613
]
],
[
[
958,
24,
250
],
[
250,
24,
1613
]
],
[
[
958,
63,
593
],
[
593,
... | [
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Ginkgo biloba",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lindane"
... | Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindane may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Blinatumom... |
DB00108 | DB11703 | 1,066 | 405 | [
"DDInter1268",
"DDInter9"
] | Natalizumab | Acalabrutinib | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1066,
25,
405
]
],
[
[
1066,
25,
139
],
[
139,
24,
405
]
],
[
[
1066,
64,
58
],
[
58,
24,
405
]
],
[
[
1066,
24,
151
],
[
151,
6... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"... | Natalizumab may lead to a major life threatening interaction when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Natalizumab may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate i... |
DB01128 | DB11057 | 918 | 720 | [
"DDInter204",
"DDInter1223"
] | Bicalutamide | Mineral oil | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced b... | Moderate | 1 | [
[
[
918,
24,
720
]
],
[
[
918,
24,
927
],
[
927,
63,
720
]
],
[
[
918,
24,
1151
],
[
1151,
24,
720
]
],
[
[
918,
25,
1069
],
[
1069,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and ... |
DB01186 | DB04837 | 107 | 649 | [
"DDInter1430",
"DDInter407"
] | Pergolide | Clofedanol | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
107,
24,
649
]
],
[
[
107,
63,
1376
],
[
1376,
24,
649
]
],
[
[
107,
63,
832
],
[
832,
40,
649
]
],
[
[
107,
24,
820
],
[
820,
4... | [
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Pergolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[... | Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Pergolide may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamin... |
DB00376 | DB00514 | 1,105 | 506 | [
"DDInter1870",
"DDInter527"
] | Trihexyphenidyl | Dextromethorphan | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Moderate | 1 | [
[
[
1105,
24,
506
]
],
[
[
1105,
21,
28929
],
[
28929,
60,
506
]
],
[
[
1105,
24,
13
],
[
13,
24,
506
]
],
[
[
1105,
24,
1609
],
[
1609,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
... | Trihexyphenidyl (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Dextromethorphan (Compound)
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exa... |
DB00169 | DB01083 | 386 | 1,142 | [
"DDInter367",
"DDInter1348"
] | Cholecalciferol | Orlistat | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Minor | 0 | [
[
[
386,
23,
1142
]
],
[
[
386,
6,
8374
],
[
8374,
45,
1142
]
],
[
[
386,
75,
1331
],
[
1331,
23,
1142
]
],
[
[
386,
25,
1098
],
[
1098,
... | [
[
[
"Cholecalciferol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orlistat"
]
],
[
[
"Cholecalciferol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Cholecalciferol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Orlistat (Compound)
Cholecalciferol (Compound) resembles Ergocalciferol (Compound) and Cholecalciferol may lead to a major life threatening interaction when taken with Ergocalciferol and Ergocalciferol may cause a minor interaction that can li... |
DB00041 | DB00808 | 1,648 | 1,605 | [
"DDInter38",
"DDInter916"
] | Aldesleukin | Indapamide | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a n... | Moderate | 1 | [
[
[
1648,
24,
1605
]
],
[
[
1648,
24,
811
],
[
811,
1,
1605
]
],
[
[
1648,
24,
104
],
[
104,
63,
1605
]
],
[
[
1648,
24,
1061
],
[
1061,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that... |
DB00652 | DB00804 | 234 | 1,507 | [
"DDInter1421",
"DDInter543"
] | Pentazocine | Dicyclomine | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
234,
24,
1507
]
],
[
[
234,
21,
28817
],
[
28817,
60,
1507
]
],
[
[
234,
63,
1594
],
[
1594,
24,
1507
]
],
[
[
234,
24,
832
],
[
832,
... | [
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Pentazocine",
"{u} (Compound) causes {v} (Side Effect)",
"Vision blurred"
],
[
"Vision blurred",
"{u} (Side Ef... | Pentazocine (Compound) causes Vision blurred (Side Effect) and Vision blurred (Side Effect) is caused by Dicyclomine (Compound)
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken... |
DB06595 | DB08904 | 1,491 | 375 | [
"DDInter1214",
"DDInter342"
] | Midostaurin | Certolizumab pegol | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Major | 2 | [
[
[
1491,
25,
375
]
],
[
[
1491,
24,
200
],
[
200,
63,
375
]
],
[
[
1491,
64,
1554
],
[
1554,
24,
375
]
],
[
[
1491,
25,
1593
],
[
1593,
... | [
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Midostaurin may lead to a major life threatening interaction when taken with Colchicine and... |
DB01081 | DB01186 | 1,688 | 107 | [
"DDInter571",
"DDInter1430"
] | Diphenoxylate | Pergolide | A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Subst... | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of Parkinson’s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic tr... | Moderate | 1 | [
[
[
1688,
24,
107
]
],
[
[
1688,
63,
1594
],
[
1594,
24,
107
]
],
[
[
1688,
40,
1118
],
[
1118,
63,
107
]
],
[
[
1688,
24,
649
],
[
649,
... | [
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pergolide"
]
],
[
[
"Diphenoxylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Diphenoxylate may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Pergolide
Diphenoxylate (Compound) resembles Difenoxin (Compound) and Difenoxin may cause a moderate interaction that co... |
DB00208 | DB00580 | 1,018 | 311 | [
"DDInter1804",
"DDInter1910"
] | Ticlopidine | Valdecoxib | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Valdecoxib was removed from the Canadian, U.S., and E.U. markets in 2005 due to concerns about a possible increased risk of heart attack and stroke. | Moderate | 1 | [
[
[
1018,
24,
311
]
],
[
[
1018,
24,
506
],
[
506,
23,
311
]
],
[
[
1018,
64,
366
],
[
366,
24,
311
]
],
[
[
1018,
25,
500
],
[
500,
... | [
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valdecoxib"
]
],
[
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
... | Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a minor interaction that can limit clinical effects when taken with Valdecoxib
Ticlopidine may lead to a major life threatening interaction when taken with Eptifibatide and Eptifib... |
DB00087 | DB09331 | 599 | 745 | [
"DDInter41",
"DDInter478"
] | Alemtuzumab | Daratumumab | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Daratumumab is an immunoglobulin G1 kappa monoclonal antibody developed by Janssen and Genmab. It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind. Daratumumab was granted FDA approval on 16 November 2015. It is approved for the trea... | Moderate | 1 | [
[
[
599,
24,
745
]
],
[
[
599,
24,
139
],
[
139,
24,
745
]
],
[
[
599,
24,
287
],
[
287,
63,
745
]
],
[
[
599,
63,
1257
],
[
1257,
2... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daratumumab"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Daratumumab
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate... |
DB00418 | DB00792 | 536 | 832 | [
"DDInter1650",
"DDInter1878"
] | Secobarbital | Tripelennamine | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Moderate | 1 | [
[
[
536,
24,
832
]
],
[
[
536,
24,
100
],
[
100,
63,
832
]
],
[
[
536,
24,
649
],
[
649,
1,
832
]
],
[
[
536,
63,
1594
],
[
1594,
24... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelennamine"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine
Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Clo... |
DB04868 | DB09073 | 478 | 951 | [
"DDInter1293",
"DDInter1379"
] | Nilotinib | Palbociclib | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery tha... | Moderate | 1 | [
[
[
478,
24,
951
]
],
[
[
478,
23,
907
],
[
907,
62,
951
]
],
[
[
478,
64,
318
],
[
318,
23,
951
]
],
[
[
478,
23,
271
],
[
271,
23,... | [
[
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
]
],
[
[
"Nilotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
... | Nilotinib may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Palbociclib
Nilotinib may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram may cause a... |
DB01004 | DB01101 | 563 | 60 | [
"DDInter806",
"DDInter285"
] | Ganciclovir | Capecitabine | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue. | Moderate | 1 | [
[
[
563,
24,
60
]
],
[
[
563,
21,
28701
],
[
28701,
60,
60
]
],
[
[
563,
24,
309
],
[
309,
62,
60
]
],
[
[
563,
63,
147
],
[
147,
23... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
]
],
[
[
"Ganciclovir",
"{u} (Compound) causes {v} (Side Effect)",
"Discomfort"
],
[
"Discomfort",
"{u} (Side Effect) i... | Ganciclovir (Compound) causes Discomfort (Side Effect) and Discomfort (Side Effect) is caused by Capecitabine (Compound)
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a minor interaction that can limit clinical effects when taken with C... |
DB00372 | DB01043 | 999 | 108 | [
"DDInter1793",
"DDInter1146"
] | Thiethylperazine | Memantine | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in ... | Moderate | 1 | [
[
[
999,
24,
108
]
],
[
[
999,
63,
1645
],
[
1645,
23,
108
]
],
[
[
999,
24,
506
],
[
506,
23,
108
]
],
[
[
999,
24,
1264
],
[
1264,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Memantine"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
]... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a minor interaction that can limit clinical effects when taken with Memantine
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorph... |
DB01285 | DB14409 | 708 | 1,129 | [
"DDInter445",
"DDInter867"
] | Corticotropin | Human adenovirus e serotype 4 strain cl-68578 antigen | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
708,
24,
1129
]
],
[
[
708,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
708,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
708,
63,
1184
],
[
1184,
... | [
[
[
"Corticotropin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Corticotropin",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Corticotropin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Corticotropin may cause a moderate interaction that could exacerbate diseases whe... |
DB00562 | DB00959 | 1,014 | 1,486 | [
"DDInter188",
"DDInter1191"
] | Benzthiazide | Methylprednisolone | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1014,
24,
1486
]
],
[
[
1014,
24,
175
],
[
175,
40,
1486
]
],
[
[
1014,
24,
167
],
[
167,
1,
1486
]
],
[
[
1014,
63,
251
],
[
251,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resemb... |
DB00651 | DB13139 | 746 | 1,032 | [
"DDInter613",
"DDInter1063"
] | Dyphylline | Levosalbutamol | Dyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective ... | Moderate | 1 | [
[
[
746,
24,
1032
]
],
[
[
746,
23,
22
],
[
22,
24,
1032
]
],
[
[
746,
24,
659
],
[
659,
24,
1032
]
],
[
[
746,
40,
1031
],
[
1031,
... | [
[
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Dyphylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ephedrine"
],
[
... | Dyphylline may cause a minor interaction that can limit clinical effects when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilant... |
DB09043 | DB13007 | 135 | 1,060 | [
"DDInter36",
"DDInter642"
] | Albiglutide | Enfortumab vedotin | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
135,
24,
1060
]
],
[
[
135,
63,
590
],
[
590,
24,
1060
]
],
[
[
135,
62,
1647
],
[
1647,
24,
1060
]
],
[
[
135,
24,
1296
],
[
1296,
... | [
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Albiglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
... | Albiglutide may cause a moderate interaction that could exacerbate diseases when taken with Acetohexamide and Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Albiglutide may cause a minor interaction that can limit clinical effects when taken with Acarbos... |
DB00197 | DB00819 | 1,324 | 471 | [
"DDInter1881",
"DDInter15"
] | Troglitazone | Acetazolamide | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its ... | Moderate | 1 | [
[
[
1324,
24,
471
]
],
[
[
1324,
24,
997
],
[
997,
40,
471
]
],
[
[
1324,
24,
761
],
[
761,
63,
471
]
],
[
[
1324,
24,
1674
],
[
1674,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetazolamide"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methazolamide"
]... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Methazolamide and Methazolamide (Compound) resembles Acetazolamide (Compound)
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interac... |
DB11718 | DB14840 | 927 | 861 | [
"DDInter640",
"DDInter1601"
] | Encorafenib | Ripretinib | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
927,
24,
861
]
],
[
[
927,
25,
351
],
[
351,
24,
861
]
],
[
[
927,
63,
353
],
[
353,
24,
861
]
],
[
[
927,
24,
1476
],
[
1476,
2... | [
[
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribocicl... | Encorafenib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin and Griseofulvin may ... |
DB01222 | DB11988 | 617 | 270 | [
"DDInter246",
"DDInter1321"
] | Budesonide | Ocrelizumab | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
617,
24,
270
]
],
[
[
617,
23,
1193
],
[
1193,
23,
270
]
],
[
[
617,
62,
1461
],
[
1461,
23,
270
]
],
[
[
617,
24,
713
],
[
713,
... | [
[
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Budesonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[... | Budesonide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Budesonide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vita... |
DB08820 | DB14730 | 1,478 | 1,412 | [
"DDInter997",
"DDInter264"
] | Ivacaftor | Calaspargase pegol | Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
1478,
24,
1412
]
],
[
[
1478,
63,
792
],
[
792,
24,
1412
]
],
[
[
1478,
24,
159
],
[
159,
24,
1412
]
],
[
[
1478,
64,
1419
],
[
1419,
... | [
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
... | Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib... |
DB00258 | DB06210 | 666 | 72 | [
"DDInter270",
"DDInter631"
] | Calcium acetate | Eltrombopag | The chemical compound calcium acetate is the calcium salt of acetic acid. It has been commonly referred to as the acetate of lime. The anhydrous form is very hygroscopic, therefore the monohydrate is the common form. | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Moderate | 1 | [
[
[
666,
24,
72
]
],
[
[
666,
24,
1292
],
[
1292,
63,
72
]
],
[
[
666,
25,
627
],
[
627,
63,
72
]
],
[
[
666,
24,
1292
],
[
1292,
25... | [
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
]
],
[
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deferiprone"
... | Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Deferiprone and Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag
Calcium acetate may lead to a major life threatening interaction when taken with Bictegravir and Bictegr... |
DB00388 | DB01132 | 1,636 | 1,130 | [
"DDInter1453",
"DDInter1472"
] | Phenylephrine | Pioglitazone | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1636,
24,
1130
]
],
[
[
1636,
21,
28661
],
[
28661,
60,
1130
]
],
[
[
1636,
24,
688
],
[
688,
24,
1130
]
],
[
[
1636,
23,
1399
],
[
13... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Phenylephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Acute coronary syndrome"
],
[
"Acute coronary syndrom... | Phenylephrine (Compound) causes Acute coronary syndrome (Side Effect) and Acute coronary syndrome (Side Effect) is caused by Pioglitazone (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerb... |
DB00197 | DB00559 | 1,324 | 152 | [
"DDInter1881",
"DDInter223"
] | Troglitazone | Bosentan | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Moderate | 1 | [
[
[
1324,
24,
152
]
],
[
[
1324,
23,
608
],
[
608,
23,
152
]
],
[
[
1324,
63,
168
],
[
168,
23,
152
]
],
[
[
1324,
24,
1613
],
[
1613,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
... | Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Bosentan
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib... |
DB00414 | DB01309 | 590 | 1,254 | [
"DDInter16",
"DDInter933"
] | Acetohexamide | Insulin glulisine | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
590,
24,
1254
]
],
[
[
590,
62,
333
],
[
333,
23,
1254
]
],
[
[
590,
24,
1033
],
[
1033,
63,
1254
]
],
[
[
590,
24,
1424
],
[
1424,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lipoic acid"
... | Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Lipoic acid and Lipoic acid may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib ... |
DB00424 | DB06702 | 19 | 573 | [
"DDInter896",
"DDInter731"
] | Hyoscyamine | Fesoterodine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
19,
24,
573
]
],
[
[
19,
24,
211
],
[
211,
1,
573
]
],
[
[
19,
63,
494
],
[
494,
1,
573
]
],
[
[
19,
6,
2720
],
[
2720,
45,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Fesoterodine... |
DB01041 | DB01095 | 770 | 671 | [
"DDInter1789",
"DDInter769"
] | Thalidomide | Fluvastatin | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
770,
24,
671
]
],
[
[
770,
24,
788
],
[
788,
40,
671
]
],
[
[
770,
24,
14
],
[
14,
63,
671
]
],
[
[
770,
6,
7950
],
[
7950,
45,
... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction... |
DB00047 | DB00701 | 176 | 1,091 | [
"DDInter932",
"DDInter90"
] | Insulin glargine | Amprenavir | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Amprenavir is a protease inhibitor used to treat HIV infection. | Moderate | 1 | [
[
[
176,
24,
1091
]
],
[
[
176,
24,
34
],
[
34,
1,
1091
]
],
[
[
176,
24,
222
],
[
222,
62,
1091
]
],
[
[
176,
24,
1151
],
[
1151,
6... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amprenavir"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosamprenavir"
... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fosamprenavir and Fosamprenavir (Compound) resembles Amprenavir (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor inter... |
DB00708 | DB06168 | 1,454 | 1,531 | [
"DDInter1718",
"DDInter281"
] | Sufentanil | Canakinumab | Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to w... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1454,
24,
1531
]
],
[
[
1454,
24,
1362
],
[
1362,
63,
1531
]
],
[
[
1454,
24,
1213
],
[
1213,
24,
1531
]
],
[
[
1454,
1,
704
],
[
704,... | [
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Sufentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
... | Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Sufentanil may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib ... |
DB01175 | DB01254 | 318 | 1,213 | [
"DDInter672",
"DDInter484"
] | Escitalopram | Dasatinib | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Major | 2 | [
[
[
318,
25,
1213
]
],
[
[
318,
6,
8374
],
[
8374,
45,
1213
]
],
[
[
318,
18,
6351
],
[
6351,
57,
1213
]
],
[
[
318,
7,
8587
],
[
8587,
... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
]
],
[
[
"Escitalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dasa... | Escitalopram (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Escitalopram (Compound) downregulates COTL1 (Gene) and COTL1 (Gene) is downregulated by Dasatinib (Compound)
Escitalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is downregulated by Dasatinib (Compound)
Escitalopra... |
DB00791 | DB01041 | 132 | 770 | [
"DDInter1902",
"DDInter1789"
] | Uracil mustard | Thalidomide | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
132,
25,
770
]
],
[
[
132,
24,
4
],
[
4,
63,
770
]
],
[
[
132,
24,
563
],
[
563,
24,
770
]
],
[
[
132,
63,
597
],
[
597,
24,
... | [
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],... | Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Uracil mustard may cause a moderate interaction that could exacerbate disease... |
DB00489 | DB01075 | 17 | 1,376 | [
"DDInter1704",
"DDInter569"
] | Sotalol | Diphenhydramine | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnoti... | Moderate | 1 | [
[
[
17,
24,
1376
]
],
[
[
17,
25,
11
],
[
11,
1,
1376
]
],
[
[
17,
25,
401
],
[
401,
24,
1376
]
],
[
[
17,
25,
888
],
[
888,
25,
... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene"... | Sotalol may lead to a major life threatening interaction when taken with Toremifene and Toremifene (Compound) resembles Diphenhydramine (Compound)
Sotalol may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when t... |
DB00344 | DB09241 | 1,302 | 1,629 | [
"DDInter1543",
"DDInter1186"
] | Protriptyline | Methylene blue | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs ... | Major | 2 | [
[
[
1302,
25,
1629
]
],
[
[
1302,
24,
1148
],
[
1148,
24,
1629
]
],
[
[
1302,
25,
874
],
[
874,
24,
1629
]
],
[
[
1302,
63,
73
],
[
73,
... | [
[
[
"Protriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Protriptyline may lead to a major life threatening interaction when taken with Epinephrine and Epinep... |
DB00294 | DB00302 | 1,336 | 335 | [
"DDInter701",
"DDInter1844"
] | Etonogestrel | Tranexamic acid | Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel. The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001. | Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent. It was first patented in 1957 and received its initial US approval in 1986. | Major | 2 | [
[
[
1336,
25,
335
]
],
[
[
1336,
21,
29276
],
[
29276,
60,
335
]
],
[
[
1336,
40,
35
],
[
35,
64,
335
]
],
[
[
1336,
25,
350
],
[
350,
... | [
[
[
"Etonogestrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tranexamic acid"
]
],
[
[
"Etonogestrel",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) is caused... | Etonogestrel (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Tranexamic acid (Compound)
Etonogestrel (Compound) resembles Quinestrol (Compound) and Quinestrol may lead to a major life threatening interaction when taken with Tranexamic acid
Etonogestrel may lead to a major life thr... |
DB00002 | DB05351 | 1,284 | 101 | [
"DDInter344",
"DDInter519"
] | Cetuximab | Dexlansoprazole | Cetuximab is a recombinant chimeric human/mouse IgG1 monoclonal antibody that competitively binds to epidermal growth factor receptor (EGFR) and competitively inhibits the binding of epidermal growth factor (EGF). EGFR is a member of the ErbB family of receptor tyrosine kinases found in both normal and tumour cells; it... | Dexlansoprazole is a new-generation proton pump inhibitor (PPI) used for the management of symptoms associated with gastroesophageal reflux disease (GERD) and erosive esophagitis. Dexlansoprazole is the R-enantiomer of , which is composed of a racemic mixture of the R- and S-enantiomers. Compared to the older generatio... | Moderate | 1 | [
[
[
1284,
24,
101
]
],
[
[
1284,
24,
589
],
[
589,
24,
101
]
],
[
[
1284,
24,
1215
],
[
1215,
23,
263
],
[
263,
62,
101
]
],
[
[
1284,
... | [
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexlansoprazole"
]
],
[
[
"Cetuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
... | Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Dexlansoprazole
Cetuximab may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lan... |
DB09046 | DB09054 | 1,094 | 384 | [
"DDInter1201",
"DDInter905"
] | Metreleptin | Idelalisib | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
1094,
24,
384
]
],
[
[
1094,
24,
907
],
[
907,
62,
384
]
],
[
[
1094,
63,
1618
],
[
1618,
24,
384
]
],
[
[
1094,
24,
466
],
[
466,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doravirine"
],
[
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabo... |
DB00717 | DB08882 | 1,197 | 1,281 | [
"DDInter1312",
"DDInter1070"
] | Norethisterone | Linagliptin | Norethisterone, also known as norethindrone, is a synthetic progestational hormone belonging to the 19-nortestosterone-derived class of progestins. It is further classified as a second-generation progestin, along with [levonorgestrel] and its derivatives, and is the active form of several other progestins including [no... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
1197,
24,
1281
]
],
[
[
1197,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
1197,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
1197,
21,
28729
],
[
287... | [
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Norethisterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],... | Norethisterone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Norethisterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Norethisterone (Compound) causes Pain in extremity (Side... |
DB01095 | DB09054 | 671 | 384 | [
"DDInter769",
"DDInter905"
] | Fluvastatin | Idelalisib | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
671,
24,
384
]
],
[
[
671,
24,
72
],
[
72,
24,
384
]
],
[
[
671,
63,
305
],
[
305,
24,
384
]
],
[
[
671,
1,
788
],
[
788,
24,
... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
[... | Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Esch... |
DB00745 | DB06616 | 307 | 594 | [
"DDInter1236",
"DDInter224"
] | Modafinil | Bosutinib | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Major | 2 | [
[
[
307,
25,
594
]
],
[
[
307,
62,
883
],
[
883,
1,
594
]
],
[
[
307,
6,
8374
],
[
8374,
45,
594
]
],
[
[
307,
21,
29231
],
[
29231,
... | [
[
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
... | Modafinil may cause a minor interaction that can limit clinical effects when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Modafinil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Modafinil (Compound) causes Cardiac disorder (Side Effect) and Cardiac dis... |
DB00515 | DB06168 | 589 | 1,531 | [
"DDInter387",
"DDInter281"
] | Cisplatin | Canakinumab | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also incl... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
589,
24,
1531
]
],
[
[
589,
63,
1461
],
[
1461,
23,
1531
]
],
[
[
589,
63,
377
],
[
377,
24,
1531
]
],
[
[
589,
24,
1270
],
[
1270,
... | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin ma... |
DB00801 | DB01142 | 1,563 | 1,264 | [
"DDInter850",
"DDInter593"
] | Halazepam | Doxepin | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1563,
24,
1264
]
],
[
[
1563,
24,
401
],
[
401,
24,
1264
]
],
[
[
1563,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
1563,
24,
392
],
[
392,
... | [
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylam... |
DB00888 | DB08826 | 1,001 | 1,292 | [
"DDInter1133",
"DDInter489"
] | Mechlorethamine | Deferiprone | A vesicant and necrotizing irritant destructive to mucous membranes, mechlorethamine is an alkylating drug. It was formerly used as a war gas. The hydrochloride is used as an antineoplastic in Hodgkin's disease and lymphomas. It causes severe gastrointestinal and bone marrow damage. The FDA granted marketing approval f... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
1001,
25,
1292
]
],
[
[
1001,
21,
28809
],
[
28809,
60,
1292
]
],
[
[
1001,
63,
1419
],
[
1419,
25,
1292
]
],
[
[
1001,
24,
4
],
[
4,
... | [
[
[
"Mechlorethamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Mechlorethamine",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused b... | Mechlorethamine (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Deferiprone (Compound)
Mechlorethamine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may lead to a major life threatening interaction when taken with Deferiprone
Mec... |
DB00801 | DB06282 | 1,563 | 516 | [
"DDInter850",
"DDInter1053"
] | Halazepam | Levocetirizine | Halazepam is a _benzodiazepine_ derivative drug exerting anxiolytic, anticonvulsant, sedative, a muscle relaxing effects.[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1563,
24,
516
]
],
[
[
1563,
62,
1031
],
[
1031,
23,
516
]
],
[
[
1563,
24,
1074
],
[
1074,
63,
516
]
],
[
[
1563,
63,
701
],
[
701,
... | [
[
[
"Halazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Halazepam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
... | Halazepam may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Halazepam may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and Io... |
DB00836 | DB01263 | 543 | 859 | [
"DDInter1088",
"DDInter1494"
] | Loperamide | Posaconazole | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Major | 2 | [
[
[
543,
25,
859
]
],
[
[
543,
6,
4973
],
[
4973,
45,
859
]
],
[
[
543,
21,
28762
],
[
28762,
60,
859
]
],
[
[
543,
24,
112
],
[
112,
... | [
[
[
"Loperamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Posaconazole"
]
],
[
[
"Loperamide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Posacon... | Loperamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Posaconazole (Compound)
Loperamide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Posaconazole (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and M... |
DB00622 | DB00789 | 1,081 | 1,431 | [
"DDInter1287",
"DDInter796"
] | Nicardipine | Gadopentetic acid | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706) | Moderate | 1 | [
[
[
1081,
24,
1431
]
],
[
[
1081,
21,
28658
],
[
28658,
60,
1431
]
],
[
[
1081,
40,
854
],
[
854,
24,
1431
]
],
[
[
1081,
24,
1013
],
[
10... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadopentetic acid"
]
],
[
[
"Nicardipine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) ... | Nicardipine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Gadopentetic acid (Compound)
Nicardipine (Compound) resembles Nimodipine (Compound) and Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Gadopentetic acid
Nicardipine may cause a modera... |
DB00196 | DB00843 | 600 | 479 | [
"DDInter743",
"DDInter583"
] | Fluconazole | Donepezil | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Minor | 0 | [
[
[
600,
23,
479
]
],
[
[
600,
24,
843
],
[
843,
1,
479
]
],
[
[
600,
6,
8374
],
[
8374,
45,
479
]
],
[
[
600,
21,
28940
],
[
28940,
... | [
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
]
],
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
],
[
... | Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine and Tetrabenazine (Compound) resembles Donepezil (Compound)
Fluconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Donepezil (Compound)
Fluconazole (Compound) causes Blood alkaline phosphatase inc... |
DB00996 | DB01105 | 1,198 | 222 | [
"DDInter791",
"DDInter1665"
] | Gabapentin | Sibutramine | Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to tr... | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1198,
24,
222
]
],
[
[
1198,
7,
2384
],
[
2384,
46,
222
]
],
[
[
1198,
18,
4360
],
[
4360,
57,
222
]
],
[
[
1198,
21,
28737
],
[
28737... | [
[
[
"Gabapentin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Gabapentin",
"{u} (Compound) upregulates {v} (Gene)",
"CDK6"
],
[
"CDK6",
"{u} (Gene) is upregulated by {v} (Co... | Gabapentin (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Sibutramine (Compound)
Gabapentin (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Sibutramine (Compound)
Gabapentin (Compound) causes Bursitis (Side Effect) and Bursitis (Side Effect) is caused by Sibutramine (Com... |
DB00222 | DB00348 | 245 | 254 | [
"DDInter825",
"DDInter1300"
] | Glimepiride | Nitisinone | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Moderate | 1 | [
[
[
245,
24,
254
]
],
[
[
245,
21,
29047
],
[
29047,
60,
254
]
],
[
[
245,
24,
1144
],
[
1144,
63,
254
]
],
[
[
245,
63,
1028
],
[
1028,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
]
],
[
[
"Glimepiride",
"{u} (Compound) causes {v} (Side Effect)",
"Hepatic function abnormal"
],
[
"Hepatic function abnormal"... | Glimepiride (Compound) causes Hepatic function abnormal (Side Effect) and Hepatic function abnormal (Side Effect) is caused by Nitisinone (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerb... |
DB00352 | DB12674 | 482 | 975 | [
"DDInter1814",
"DDInter1105"
] | Tioguanine | Lurbinectedin | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma, chronic lymphocytic leukemia (CLL), breast cancer, and small-cell lung cancer (SCLC). It is a derivative of the marine-derived agent ecteinascidin ([trabectedin]), an anticancer agent fou... | Moderate | 1 | [
[
[
482,
24,
975
]
],
[
[
482,
24,
1613
],
[
1613,
24,
975
]
],
[
[
482,
24,
159
],
[
159,
63,
975
]
],
[
[
482,
63,
1560
],
[
1560,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurbinectedin"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Lurbinectedin
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01202 | DB01611 | 1,435 | 1,487 | [
"DDInter1046",
"DDInter893"
] | Levetiracetam | Hydroxychloroquine | Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam poss... | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1435,
24,
1487
]
],
[
[
1435,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
1435,
62,
663
],
[
663,
23,
1487
]
],
[
[
1435,
63,
770
],
[
770... | [
[
[
"Levetiracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Levetiracetam",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Eff... | Levetiracetam (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Levetiracetam may cause a minor interaction that can limit clinical effects when taken with Methotrexate and Methotrexate may cause a minor interaction that can limit clinical effects when taken ... |
DB01004 | DB11793 | 563 | 738 | [
"DDInter806",
"DDInter1297"
] | Ganciclovir | Niraparib | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
563,
24,
738
]
],
[
[
563,
24,
1213
],
[
1213,
24,
738
]
],
[
[
563,
63,
663
],
[
663,
24,
738
]
],
[
[
563,
24,
1619
],
[
1619,
... | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
... | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Metho... |
DB01577 | DB06655 | 1,529 | 5 | [
"DDInter1161",
"DDInter1077"
] | Metamfetamine | Liraglutide | Metamfetamine (methamphetamine) is a psychostimulant and sympathomimetic drug, and a member of the amphetamine group of sympathomimetic amines. Methamphetamine can induce effects such as euphoria, increased alertness and energy, and enhanced self-esteem. It is a scheduled drug in most countries due to its high potentia... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
1529,
24,
5
]
],
[
[
1529,
63,
245
],
[
245,
24,
5
]
],
[
[
1529,
74,
1445
],
[
1445,
24,
5
]
],
[
[
1529,
75,
73
],
[
73,
24,
... | [
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Metamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Metamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Metamfetamine (Compound) resembles Pseudoephedrine (Compound) and Metamfetamine may cause a moderate inter... |
DB00731 | DB01144 | 1,144 | 1,326 | [
"DDInter1269",
"DDInter540"
] | Nateglinide | Diclofenamide | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Moderate | 1 | [
[
[
1144,
24,
1326
]
],
[
[
1144,
24,
504
],
[
504,
1,
1326
]
],
[
[
1144,
24,
359
],
[
359,
40,
1326
]
],
[
[
1144,
6,
6017
],
[
6017,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide and Hydrochlorothiazide (Compound) resembles Diclofenamide (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Chlorothiazide and Chlorothiazide (Compound) r... |
DB00852 | DB09564 | 1,445 | 1,296 | [
"DDInter1545",
"DDInter930"
] | Pseudoephedrine | Insulin degludec | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1445,
24,
1296
]
],
[
[
1445,
23,
1203
],
[
1203,
23,
1296
]
],
[
[
1445,
63,
17
],
[
17,
24,
1296
]
],
[
[
1445,
24,
1411
],
[
1411,
... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Monopotassium... | Pseudoephedrine may cause a minor interaction that can limit clinical effects when taken with Monopotassium phosphate and Monopotassium phosphate may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases... |
DB01165 | DB01218 | 1,539 | 1,493 | [
"DDInter1325",
"DDInter852"
] | Ofloxacin | Halofantrine | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
1539,
25,
1493
]
],
[
[
1539,
21,
28810
],
[
28810,
60,
1493
]
],
[
[
1539,
62,
112
],
[
112,
23,
1493
]
],
[
[
1539,
63,
770
],
[
770... | [
[
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Ofloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect... | Ofloxacin (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Halofantrine (Compound)
Ofloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effec... |
DB06595 | DB09083 | 1,491 | 880 | [
"DDInter1214",
"DDInter996"
] | Midostaurin | Ivabradine | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1491,
25,
880
]
],
[
[
1491,
63,
480
],
[
480,
24,
880
]
],
[
[
1491,
24,
1478
],
[
1478,
24,
880
]
],
[
[
1491,
24,
159
],
[
159,
... | [
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoter... | Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivaca... |
DB00719 | DB08897 | 1,219 | 1,429 | [
"DDInter149",
"DDInter22"
] | Azatadine | Aclidinium | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012. | Moderate | 1 | [
[
[
1219,
24,
1429
]
],
[
[
1219,
63,
352
],
[
352,
24,
1429
]
],
[
[
1219,
24,
1511
],
[
1511,
24,
1429
]
],
[
[
1219,
24,
1116
],
[
1116... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aclidinium"
]
],
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
... | Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Aclidinium
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate... |
DB04845 | DB09054 | 309 | 384 | [
"DDInter1001",
"DDInter905"
] | Ixabepilone | Idelalisib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
309,
24,
384
]
],
[
[
309,
24,
555
],
[
555,
23,
384
]
],
[
[
309,
62,
307
],
[
307,
23,
384
]
],
[
[
309,
63,
289
],
[
289,
24,... | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Netupitant"
],
[
... | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil... |
DB00461 | DB01222 | 598 | 617 | [
"DDInter1254",
"DDInter246"
] | Nabumetone | Budesonide | Nabumetone was originally developed as a non-acidic non-steroidal anti-inflammatory drug (NSAID).[label] It was thought to avoid trapping of the drug in the stomach by making it unable to dissociate into ions which was believed to reduce GI toxicity by limiting local action. While slightly reduced, possibly due to a de... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
598,
24,
617
]
],
[
[
598,
63,
251
],
[
251,
1,
617
]
],
[
[
598,
24,
175
],
[
175,
1,
617
]
],
[
[
598,
18,
3106
],
[
3106,
57,... | [
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Nabumetone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[... | Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Nabumetone may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Budesonide... |
DB00477 | DB00526 | 216 | 1,555 | [
"DDInter363",
"DDInter1355"
] | Chlorpromazine | Oxaliplatin | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Moderate | 1 | [
[
[
216,
24,
1555
]
],
[
[
216,
6,
7950
],
[
7950,
45,
1555
]
],
[
[
216,
63,
79
],
[
79,
24,
1555
]
],
[
[
216,
24,
1213
],
[
1213,
... | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Co... | Chlorpromazine (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Oxaliplatin (Compound)
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin
Chlorproma... |
DB00414 | DB01083 | 590 | 1,142 | [
"DDInter16",
"DDInter1348"
] | Acetohexamide | Orlistat | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Moderate | 1 | [
[
[
590,
24,
1142
]
],
[
[
590,
24,
5
],
[
5,
63,
1142
]
],
[
[
590,
24,
1144
],
[
1144,
24,
1142
]
],
[
[
590,
63,
798
],
[
798,
24... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
],
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide and Liraglutide may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and... |
DB00059 | DB01009 | 1,560 | 935 | [
"DDInter1404",
"DDInter1009"
] | Pegaspargase | Ketoprofen | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Moderate | 1 | [
[
[
1560,
24,
935
]
],
[
[
1560,
24,
1523
],
[
1523,
40,
935
]
],
[
[
1560,
24,
847
],
[
847,
1,
935
]
],
[
[
1560,
24,
1274
],
[
1274,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketoprofen"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
],
[... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Labetalol and Labetalol (Compound) resembles Ketoprofen (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Atomoxetine and Atomoxetine (Compound) resembles Ketoprofen (Compou... |
DB00307 | DB00843 | 1,101 | 479 | [
"DDInter202",
"DDInter583"
] | Bexarotene | Donepezil | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and i... | Moderate | 1 | [
[
[
1101,
24,
479
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
479
]
],
[
[
1101,
21,
29015
],
[
29015,
60,
479
]
],
[
[
1101,
23,
760
],
[
760,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Donepezil (Compound)
Bexarotene (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Donepezil (Compound)
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat and Co... |
DB00342 | DB09118 | 1,181 | 1,580 | [
"DDInter1770",
"DDInter1711"
] | Terfenadine | Stiripentol | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
1181,
24,
1580
]
],
[
[
1181,
24,
283
],
[
283,
63,
1580
]
],
[
[
1181,
24,
79
],
[
79,
24,
1580
]
],
[
[
1181,
25,
478
],
[
478,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sora... |
DB01142 | DB01242 | 1,264 | 1,237 | [
"DDInter593",
"DDInter410"
] | Doxepin | Clomipramine | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Moderate | 1 | [
[
[
1264,
35,
1237
]
],
[
[
1264,
64,
684
],
[
684,
1,
1237
]
],
[
[
1264,
1,
11275
],
[
11275,
40,
1237
]
],
[
[
1264,
74,
1164
],
[
1164... | [
[
[
"Doxepin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Th... | Doxepin (Compound) resembles Clomipramine (Compound) and
Doxepin may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Clomipramine (Compound)
Doxepin (Compound) resembles Chlorprothixene (Compound) and Chlorprothixene (Compound) resembles Clomipramine (Comp... |
DB00349 | DB01069 | 902 | 401 | [
"DDInter401",
"DDInter1533"
] | Clobazam | Promethazine | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
902,
24,
401
]
],
[
[
902,
24,
1264
],
[
1264,
63,
401
]
],
[
[
902,
1,
1321
],
[
1321,
40,
401
]
],
[
[
902,
40,
1237
],
[
1237,
... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"... | Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Clobazam (Compound) resembles Prochlorperazine (Compound) and Prochlorperazine (Compound) resembles Promethazine (Comp... |
DB06616 | DB12332 | 594 | 1,619 | [
"DDInter224",
"DDInter1626"
] | Bosutinib | Rucaparib | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
594,
24,
1619
]
],
[
[
594,
64,
307
],
[
307,
23,
1619
]
],
[
[
594,
62,
112
],
[
112,
23,
1619
]
],
[
[
594,
63,
259
],
[
259,
... | [
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Modafinil"
],
[
"Modafinil",
... | Bosutinib may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Bosutinib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a m... |
DB00902 | DB09237 | 104 | 1,586 | [
"DDInter1168",
"DDInter1045"
] | Methdilazine | Levamlodipine | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
104,
24,
1586
]
],
[
[
104,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
104,
24,
549
],
[
549,
24,
1586
]
],
[
[
104,
25,
593
],
[
593,
... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozi... |
DB06081 | DB11703 | 1,046 | 405 | [
"DDInter286",
"DDInter9"
] | Caplacizumab | Acalabrutinib | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Major | 2 | [
[
[
1046,
25,
405
]
],
[
[
1046,
63,
383
],
[
383,
24,
405
]
],
[
[
1046,
24,
643
],
[
643,
24,
405
]
],
[
[
1046,
25,
1598
],
[
1598,
... | [
[
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
]
],
[
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
... | Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Acalabrutinib
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken... |
DB00344 | DB01254 | 1,302 | 1,213 | [
"DDInter1543",
"DDInter484"
] | Protriptyline | Dasatinib | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Moderate | 1 | [
[
[
1302,
24,
1213
]
],
[
[
1302,
6,
4973
],
[
4973,
45,
1213
]
],
[
[
1302,
7,
10167
],
[
10167,
46,
1213
]
],
[
[
1302,
18,
4046
],
[
40... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Protriptyline",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound... | Protriptyline (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Protriptyline (Compound) upregulates MAP7 (Gene) and MAP7 (Gene) is upregulated by Dasatinib (Compound)
Protriptyline (Compound) downregulates PIK3C2B (Gene) and PIK3C2B (Gene) is upregulated by Dasatinib (Compound)
Protriptyl... |
DB00108 | DB01157 | 1,066 | 304 | [
"DDInter1268",
"DDInter1875"
] | Natalizumab | Trimetrexate | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Major | 2 | [
[
[
1066,
25,
304
]
],
[
[
1066,
64,
58
],
[
58,
24,
304
]
],
[
[
1066,
24,
1270
],
[
1270,
63,
304
]
],
[
[
1066,
25,
1613
],
[
1613,
... | [
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimetrexate"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u}... | Natalizumab may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein deriva... |
DB00853 | DB08826 | 1,686 | 1,292 | [
"DDInter1762",
"DDInter489"
] | Temozolomide | Deferiprone | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Major | 2 | [
[
[
1686,
25,
1292
]
],
[
[
1686,
21,
28759
],
[
28759,
60,
1292
]
],
[
[
1686,
63,
482
],
[
482,
25,
1292
]
],
[
[
1686,
24,
4
],
[
4,
... | [
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
]
],
[
[
"Temozolomide",
"{u} (Compound) causes {v} (Side Effect)",
"Connective tissue disorder"
],
[
"Connective tissue disorder",
"{... | Temozolomide (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Deferiprone (Compound)
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may lead to a major life threatening interaction... |
DB00204 | DB09020 | 228 | 28 | [
"DDInter580",
"DDInter212"
] | Dofetilide | Bisacodyl | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
228,
24,
28
]
],
[
[
228,
18,
4930
],
[
4930,
57,
28
]
],
[
[
228,
21,
28809
],
[
28809,
60,
28
]
],
[
[
228,
40,
540
],
[
540,
... | [
[
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Dofetilide",
"{u} (Compound) downregulates {v} (Gene)",
"DLD"
],
[
"DLD",
"{u} (Gene) is downregulated by {v} (Co... | Dofetilide (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Bisacodyl (Compound)
Dofetilide (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Bisacodyl (Compound)
Dofetilide (Compound) resembles Dronedarone (Compound) and Dronedarone may cause a moderate interactio... |
DB01059 | DB11901 | 956 | 913 | [
"DDInter1313",
"DDInter107"
] | Norfloxacin | Apalutamide | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
956,
24,
913
]
],
[
[
956,
62,
112
],
[
112,
23,
913
]
],
[
[
956,
63,
600
],
[
600,
24,
913
]
],
[
[
956,
24,
28
],
[
28,
24,
... | [
[
[
"Norfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and ... |
DB01073 | DB01095 | 1,488 | 671 | [
"DDInter745",
"DDInter769"
] | Fludarabine | Fluvastatin | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Moderate | 1 | [
[
[
1488,
24,
671
]
],
[
[
1488,
24,
788
],
[
788,
40,
671
]
],
[
[
1488,
24,
14
],
[
14,
63,
671
]
],
[
[
1488,
21,
28769
],
[
28769,
... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Fluvastatin (Compound)
Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction... |
DB01611 | DB06176 | 1,487 | 1,342 | [
"DDInter893",
"DDInter1616"
] | Hydroxychloroquine | Romidepsin | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Major | 2 | [
[
[
1487,
25,
1342
]
],
[
[
1487,
62,
1247
],
[
1247,
23,
1342
]
],
[
[
1487,
63,
112
],
[
112,
23,
1342
]
],
[
[
1487,
64,
956
],
[
956,
... | [
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Hydroxychloroquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
... | Hydroxychloroquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00047 | DB06710 | 176 | 1,546 | [
"DDInter932",
"DDInter1193"
] | Insulin glargine | Methyltestosterone | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | A synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. Also, has antineoplastic properties and so has been used secondarily in women with advanced breast cancer. Methyltestosterone is a schedule III drug in the US. | Moderate | 1 | [
[
[
176,
24,
1546
]
],
[
[
176,
24,
155
],
[
155,
1,
1546
]
],
[
[
176,
24,
984
],
[
984,
40,
1546
]
],
[
[
176,
24,
1486
],
[
1486,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxym... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxymesterone and Fluoxymesterone (Compound) resembles Methyltestosterone (Compound)
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol (Compound) resemble... |
DB00563 | DB09054 | 663 | 384 | [
"DDInter1174",
"DDInter905"
] | Methotrexate | Idelalisib | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
663,
24,
384
]
],
[
[
663,
24,
1627
],
[
1627,
62,
384
]
],
[
[
663,
24,
72
],
[
72,
24,
384
]
],
[
[
663,
24,
725
],
[
725,
63,... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and E... |
DB00209 | DB09076 | 352 | 1,116 | [
"DDInter1886",
"DDInter1899"
] | Trospium | Umeclidinium | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | Umeclidinium is a long-acting muscarinic antagonist (LAMA) used as a maintenance treatment for symptoms of chronic obstructive pulmonary disease (COPD). COPD is a progressive obstructive lung disease characterized by shortness of breath, cough, sputum production, and chronically poor airflow with a forced expiratory vo... | Moderate | 1 | [
[
[
352,
24,
1116
]
],
[
[
352,
24,
849
],
[
849,
24,
1116
]
],
[
[
352,
35,
194
],
[
194,
24,
1116
]
],
[
[
352,
24,
337
],
[
337,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Umeclidinium"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Umeclidinium
Trospium (Compound) resembles Darifenacin (Compound) and Trospium may cause a moderate interaction that could ex... |
DB00242 | DB12015 | 1,064 | 1,033 | [
"DDInter392",
"DDInter53"
] | Cladribine | Alpelisib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1064,
24,
1033
]
],
[
[
1064,
25,
738
],
[
738,
24,
1033
]
],
[
[
1064,
24,
1612
],
[
1612,
24,
1033
]
],
[
[
1064,
25,
1619
],
[
1619... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niraparib"
],
[
"Niraparib",
... | Cladribine may lead to a major life threatening interaction when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a... |
DB00734 | DB11113 | 1,664 | 657 | [
"DDInter1605",
"DDInter307"
] | Risperidone | Castor oil | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1664,
24,
657
]
],
[
[
1664,
24,
927
],
[
927,
63,
657
]
],
[
[
1664,
24,
1491
],
[
1491,
24,
657
]
],
[
[
1664,
25,
985
],
[
985,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and M... |
DB00444 | DB12887 | 63 | 1,598 | [
"DDInter1765",
"DDInter1750"
] | Teniposide | Tazemetostat | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
63,
24,
1598
]
],
[
[
63,
63,
168
],
[
168,
23,
1598
]
],
[
[
63,
24,
310
],
[
310,
24,
1598
]
],
[
[
63,
63,
134
],
[
134,
24,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Tazemetostat
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabaz... |
DB01224 | DB01278 | 623 | 1,021 | [
"DDInter1553",
"DDInter1506"
] | Quetiapine | Pramlintide | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
623,
24,
1021
]
],
[
[
623,
63,
1507
],
[
1507,
24,
1021
]
],
[
[
623,
40,
508
],
[
508,
24,
1021
]
],
[
[
623,
24,
1296
],
[
1296,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
[
... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Quetiapine (Compound) resembles Promazine (Compound) and Promazine may cause a moderate interaction that coul... |
DB00030 | DB00334 | 1,685 | 867 | [
"DDInter934",
"DDInter1326"
] | Insulin human | Olanzapine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mel... | Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug inte... | Moderate | 1 | [
[
[
1685,
24,
867
]
],
[
[
1685,
24,
695
],
[
695,
40,
867
]
],
[
[
1685,
24,
1616
],
[
1616,
63,
867
]
],
[
[
1685,
24,
1645
],
[
1645,
... | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olanzapine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
... | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine (Compound) resembles Olanzapine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that cou... |
DB00023 | DB08864 | 305 | 786 | [
"DDInter127",
"DDInter1595"
] | Asparaginase Escherichia coli | Rilpivirine | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
305,
24,
786
]
],
[
[
305,
24,
522
],
[
522,
24,
786
]
],
[
[
305,
25,
1101
],
[
1101,
24,
786
]
],
[
[
305,
24,
1228
],
[
1228,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken ... |
DB00289 | DB01364 | 847 | 22 | [
"DDInter132",
"DDInter650"
] | Atomoxetine | Ephedrine | Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve develop... | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Moderate | 1 | [
[
[
847,
35,
22
]
],
[
[
847,
24,
1445
],
[
1445,
1,
22
]
],
[
[
847,
6,
7390
],
[
7390,
45,
22
]
],
[
[
847,
18,
1954
],
[
1954,
57... | [
[
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ephedrine"
]
],
[
[
"Atomoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken ... | Atomoxetine (Compound) resembles Ephedrine (Compound) and
Atomoxetine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound)
Atomoxetine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Ephedrine (Compound... |
DB00081 | DB14711 | 273 | 779 | [
"DDInter1838",
"DDInter1680"
] | Tositumomab | Smallpox (Vaccinia) Vaccine, Live | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
273,
25,
779
]
],
[
[
273,
25,
1064
],
[
1064,
25,
779
]
],
[
[
273,
64,
581
],
[
581,
25,
779
]
],
[
[
273,
24,
270
],
[
270,
2... | [
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"... | Tositumomab may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Tositumomab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a m... |
DB00214 | DB01132 | 1,028 | 1,130 | [
"DDInter1836",
"DDInter1472"
] | Torasemide | Pioglitazone | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1028,
24,
1130
]
],
[
[
1028,
6,
6017
],
[
6017,
45,
1130
]
],
[
[
1028,
21,
28996
],
[
28996,
60,
1130
]
],
[
[
1028,
24,
688
],
[
68... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Torasemide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)... | Torasemide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Pioglitazone (Compound)
Torasemide (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Pioglitazone (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseas... |
DB00852 | DB00968 | 1,445 | 1,551 | [
"DDInter1545",
"DDInter1185"
] | Pseudoephedrine | Methyldopa | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrener... | Moderate | 1 | [
[
[
1445,
24,
1551
]
],
[
[
1445,
24,
1148
],
[
1148,
40,
1551
]
],
[
[
1445,
24,
1354
],
[
1354,
1,
1551
]
],
[
[
1445,
6,
5372
],
[
5372... | [
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyldopa"
]
],
[
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
... | Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline (Compound) resembles Methyldopa (Compound)
Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa and Droxidopa (Compound) resembles Methyldopa... |
DB00496 | DB01278 | 194 | 1,021 | [
"DDInter480",
"DDInter1506"
] | Darifenacin | Pramlintide | Darifenacin (Enablex®, Novartis) is a medication used to treat urinary incontinence. Darifenacin blocks M3 muscarinic acetylcholine receptors, which mediate bladder muscle contractions. This block reduces the urgency to urinate and so it should not be used in people with urinary retention. It is unknown if M3 receptor ... | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
194,
24,
1021
]
],
[
[
194,
24,
1507
],
[
1507,
24,
1021
]
],
[
[
194,
24,
98
],
[
98,
63,
1021
]
],
[
[
194,
35,
262
],
[
262,
... | [
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Darifenacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
],
... | Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine and Dicyclomine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Darifenacin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Som... |
DB00242 | DB00322 | 1,064 | 141 | [
"DDInter392",
"DDInter742"
] | Cladribine | Floxuridine | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Major | 2 | [
[
[
1064,
25,
141
]
],
[
[
1064,
36,
1083
],
[
1083,
40,
141
]
],
[
[
1064,
35,
1477
],
[
1477,
40,
141
]
],
[
[
1064,
24,
1279
],
[
1279,... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Floxuridine"
]
],
[
[
"Cladribine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Trifluridine... | Cladribine (Compound) resembles Trifluridine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Trifluridine and Trifluridine (Compound) resembles Floxuridine (Compound)
Cladribine (Compound) resembles Telbivudine (Compound) and Cladribine may cause a moderate interaction that co... |
DB00059 | DB00382 | 1,560 | 62 | [
"DDInter1404",
"DDInter1734"
] | Pegaspargase | Tacrine | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | A centerally active cholinesterase inhibitor that has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders. Tacrine has been discontinued for the United States market. | Moderate | 1 | [
[
[
1560,
24,
62
]
],
[
[
1560,
24,
848
],
[
848,
62,
62
]
],
[
[
1560,
24,
79
],
[
79,
63,
62
]
],
[
[
1560,
24,
482
],
[
482,
24,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tacrine"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a minor interaction that can limit clinical effects when taken with Tacrine
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib ... |
DB01176 | DB04843 | 537 | 1,511 | [
"DDInter453",
"DDInter1149"
] | Cyclizine | Mepenzolate | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
537,
24,
1511
]
],
[
[
537,
64,
675
],
[
675,
24,
1511
]
],
[
[
537,
63,
1192
],
[
1192,
24,
1511
]
],
[
[
537,
40,
11234
],
[
11234,
... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Cyclizine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dex... | Cyclizine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and Gl... |
DB00278 | DB00500 | 291 | 24 | [
"DDInter117",
"DDInter1831"
] | Argatroban | Tolmetin | Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant sh... | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Moderate | 1 | [
[
[
291,
24,
24
]
],
[
[
291,
24,
886
],
[
886,
1,
24
]
],
[
[
291,
24,
831
],
[
831,
40,
24
]
],
[
[
291,
21,
28809
],
[
28809,
60,... | [
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
]
],
[
[
"Argatroban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
],
[
... | Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac and Ketorolac (Compound) resembles Tolmetin (Compound)
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Indomethacin and Indomethacin (Compound) resembles Tolmetin (Compound)
Ar... |
DB05578 | DB09068 | 330 | 1,427 | [
"DDInter1566",
"DDInter1948"
] | Ramucirumab | Vortioxetine | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
330,
24,
1427
]
],
[
[
330,
64,
25
],
[
25,
24,
1427
]
],
[
[
330,
25,
256
],
[
256,
24,
1427
]
],
[
[
330,
25,
405
],
[
405,
63... | [
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anistreplase"
],
[
"Anis... | Ramucirumab may lead to a major life threatening interaction when taken with Anistreplase and Anistreplase may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Ramucirumab may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a moderat... |
DB00601 | DB05773 | 453 | 1,047 | [
"DDInter1073",
"DDInter1848"
] | Linezolid | Trastuzumab emtansine | Linezolid is a synthetic antibiotic which is used for the treatment of infections caused by aerobic Gram-positive bacteria. Its effects are bacteriostatic against both enterococci and staphylococci and bactericidal against most isolates of streptococci. Linezolid exerts its antibacterial activity by inhibiting the init... | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-mic... | Moderate | 1 | [
[
[
453,
24,
1047
]
],
[
[
453,
25,
375
],
[
375,
63,
1047
]
],
[
[
453,
24,
310
],
[
310,
63,
1047
]
],
[
[
453,
24,
458
],
[
458,
... | [
[
[
"Linezolid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Linezolid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
... | Linezolid may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Linezolid may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel... |
DB00446 | DB00578 | 597 | 703 | [
"DDInter351",
"DDInter295"
] | Chloramphenicol | Carbenicillin | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function. | Moderate | 1 | [
[
[
597,
24,
703
]
],
[
[
597,
63,
790
],
[
790,
40,
703
]
],
[
[
597,
24,
950
],
[
950,
40,
703
]
],
[
[
597,
6,
10612
],
[
10612,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbenicillin"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piperacillin"
... | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Piperacillin and Piperacillin (Compound) resembles Carbenicillin (Compound)
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Cloxacillin and Cloxacillin (Compound) resembles Car... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.